JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Arthritis, Psoriatic

Interventions: Drug: Guselkumab
Drug: Placebo

First Posted Date: 2017-05-18

Last Posted Date: 2022-12-22

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 741

Registration Number: NCT03158285

Locations: 🇱🇹
Siauliai Republican Hospital, Public Institution, Siauliai, Lithuania
🇵🇱
Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk, Poland
🇺🇦
Mi 'Kherson City Clinical Hospital Of E.E. Karabelesh', Kherson, Ukraine

and more 135 locations

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ODV 200 mg
Drug: ODV Placebo (Matching 25 mg ODV)
Drug: ODV Placebo (Matching 200 mg ODV)
Drug: ODV 125 mg
Drug: ODV Placebo (Matching 125 mg ODV)
Drug: SMV Placebo (Matching 150 mg SMV)
Drug: ODV Placebo (Matching 100 mg ODV)
Drug: ODV 100 mg
Drug: AL-335 Placebo (matching 1200 mg AL-335)
Drug: Moxifloxacin Placebo (matching 400 mg moxifloxacin)
Drug: ODV 25 mg
Drug: SMV 150 mg
Drug: AL-335 1200 mg

First Posted Date: 2017-05-16

Last Posted Date: 2017-11-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 59

Registration Number: NCT03155893

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Optimizing Clinical Screening and Management of Maternal Mental Health: Predicting Women at Risk for Perinatal Depression

Completed

Conditions: Depression

First Posted Date: 2017-05-09

Last Posted Date: 2019-07-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 298

Registration Number: NCT03144752

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Hematological Malignancies

Interventions: Drug: Teclistamab (IV)
Drug: Teclistamab(SC)

First Posted Date: 2017-05-09

Last Posted Date: 2025-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 282

Registration Number: NCT03145181

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects, New York, New York, United States

and more 10 locations

Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59

Phase 1

Completed

Conditions: Dry Age-related Macular Degeneration

Interventions: Biological: AAVCAGsCD59

First Posted Date: 2017-05-09

Last Posted Date: 2025-03-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 17

Registration Number: NCT03144999

Locations: 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: JNJ-61803534
Drug: Placebo
Drug: Midazolam

First Posted Date: 2017-05-04

Last Posted Date: 2018-07-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 47

Registration Number: NCT03139500

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Erdafitinib
Drug: Fluconazole
Drug: Itraconazole

First Posted Date: 2017-05-01

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 54

Registration Number: NCT03135106

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rilpivirine
Drug: Rilpivirine Long-acting Parenteral Formulation

First Posted Date: 2017-04-25

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 110

Registration Number: NCT03127189

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: JNJ-64155806 150 mg
Drug: Ethinylestradiol/drospirenone 0.02 mg/3 mg
Drug: COCP Placebo

First Posted Date: 2017-04-24

Last Posted Date: 2017-09-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT03126097

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

An Epidemiology Study of Treatment Resistant Depression in the United States (US)

Completed

Conditions: Depressive Disorder, Treatment-Resistant

First Posted Date: 2017-04-11

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 200000

Registration Number: NCT03109002

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy